

## INDEX

- 34βE12, 184, 187
- abscesses, 88–9  
amebic, 5, 217, 220  
cholangitic, 53  
eosinophilic, 217, 219, 225–9  
fungal, 217, 219  
pyogenic, 53, 217–18
- acinar tumors, 43, 46, 174
- actin, 86, 91
- Actinomyces* spp., 46, 217
- adenocarcinoma, 176  
colorectal, 176  
cystic mucinous, 55  
gallbladder, 176  
gastric, 176  
lung, 177  
metastatic, 263  
pancreatic, 176  
prostatic acinar, 178
- adenoma  
bile duct, 82–4  
hepatocellular *See* hepatocellular adenoma
- adenomatosis, liver 72
- adenosquamous carcinoma, 156, 160
- adrenocortical carcinoma, 62–4, 115, 186, 194–5  
differential diagnosis, 263
- adrenocortical cells, contamination, 5
- AE1, 259–60
- AE3, 259
- aflatoxin B1, 100
- AFP-producing adenocarcinoma from stomach, 174, 205, 208–9
- AFP-producing gastric carcinoma, 205
- Alcian Blue stain, 83, 131, 155, 174
- ALK-1, 91
- α1-antichymotrypsin, 245
- α1-antitrypsin, 245
- α-fetoprotein (AFP), 100, 117, 130, 132, 174, 205, 253–4, 262
- amebic abscess, 5, 217, 220
- American Association for the Study of Liver Disease (AASLD), 60, 101
- ampullary adenocarcinoma, metastatic, 164
- ancillary tests, 62, 250–72  
case studies, 262–7  
current best practice, 261–5  
histochemistry, 250–3, 262  
immunohistochemistry, 253–64, 266  
*See also specific tumors and markers*
- angiomyolipoma, 38–9, 52–9, 66, 84–6  
ancillary tests, 86  
clinical features, 84  
cytology, 84  
differential diagnosis, 86, 115, 174, 263–4  
histology, 84  
radiology, 84
- angiosarcoma, 39, 174, 200, 202–5, 265, 291  
ancillary tests, 205  
clinical features, 202  
cytology, 203  
differential diagnosis, 204, 266  
histology, 204  
radiology, 203
- aniline blue stain, 251
- aniline light green stain, 251
- arginase-1, 117, 256–7
- Aspergillus flavus*, 100
- Aspergillus parasiticus*, 100
- aspirates, minimum criteria, 4
- Azure A stain, 281
- bare nuclei, 48, 104, 108–9, 115, 117, 147  
HCC, 109  
ICC, 147  
shearing artifact, 278  
small cell carcinoma, 190
- Beckwith–Weidemann syndrome, 235
- benign aspirate pattern, 13, 15, 19, 33, 38
- benign focal lesions, 66–7  
diagnostic algorithm, 67  
*See also specific lesions*
- β-catenin-activated HCA, 266
- Biebrich scarlet stain, 251
- bile canaliculi, 16
- bile cytology, 140, 161
- bile duct, 16  
adenoma, 82–4  
anatomy, 17, 19  
biopsy, 157, 161  
brushing, 157, 161  
epithelial cells, 13  
obstructive dilatation, 220  
solitary cyst, 55, 219, 223  
stricture, 21, 140, 142, 158, 161, 166, 167, 168  
washing, 157
- bile duct disorders, 20–7  
clinical features, 20  
cytology, 26–7  
diagnosis, 19  
histology, 26  
radiology, 21
- bile duct hamartoma (BDH), 3, 20, 81–3, 149  
differential diagnosis, 154
- bile pigments, 21, 24, 72–3, 108, 128
- biliary adenofibroma, 82
- biliary cirrhosis, 21
- biliary intraductal papillary neoplasm, 42, 223–4  
ancillary tests, 224  
clinical features, 223  
cytology, 224, 226  
differential diagnosis, 224  
histology, 224
- biliary intraepithelial neoplasia (BilIN), 222
- biliary lesions, 42  
*See also specific tumors*
- biliary tract, 14
- biopsy  
assessment for adequacy, 4  
core needle *See* CNB  
diagnosis, 7  
algorithm for *See* diagnostic algorithms  
dilemmas in, 52, 56  
fine needle aspiration *See* FNAB  
minimum criteria, 4  
morphology, 5, 32  
nondiagnostic/nonrepresentative, 5  
operator skill, 3  
patient cooperation, 3  
reporting, 7–9, 52, 56  
ROSE *See* ROSE  
specimen handling, 3  
technique, 3–4  
*See also specific techniques*  
unsatisfactory, 4
- Bismark brown stain, 281
- blood flow in liver, 13
- blue bodies, 187
- breast  
ductal carcinoma, 41, 166, 177, 191  
metastases, 174  
lobular carcinoma, 185, 191, 264
- CA-125, 177
- CA19–9, 214
- calcification, 3, 86, 87, 89, 151, 167, 169, 202, 221, 235, 236, 242, 245
- CAM5.2, 116, 260
- canal of Hering, 19
- Candida* spp., 217, 219
- carcinoembryonic antigen *See* pCEA
- carcinoid tumor, 182, 184
- carcinoma *See specific types*
- carcinosarcoma, 205
- case studies, 9–12, 52–9, 62–5  
ancillary tests, 262–7

- cystic lesions, 225–30  
 HCC, 132–6  
 inflammatory pseudotumors, 91–7  
 intrahepatic cholangiocarcinoma, 164–9  
 metastatic tumors, 205–9  
 pediatric tumors, 234–45  
 techniques, 289–92
- caseous necrosis, 5
- cavernous hemangioma, 87, 217, 222
- CD10, 116, 132, 257–8
- CD21, 91, 202
- CD23, 202
- CD31, 202
- CD34, 68, 72–3, 77, 80, 125, 200, 202, 257–8, 262–3
- CD35, 91, 202
- CD56, 132, 183
- CD68, 91
- CD99, 239
- CD117, 86, 132, 200
- CDX2, 176, 177, 184
- cell blocks, 283–6  
 scrape/scraping method, 287  
*See also* histology
- cellular inclusions, 109
- c-erbB-2, 177, 180, 185, 264
- ceroid, 16, 21, 24
- characteristics of lesions, 3
- Charcot–Leyden crystals, 217
- cholangiocarcinoma, 139  
 cystic intrahepatic, 224  
*See also* intrahepatic cholangiocarcinoma  
 and hilar cholangiocarcinoma
- cholangitic abscess, 53
- cholangitis, 91, 167, 180, 217, 223, 246, 289  
 primary sclerosing, 20, 26, 139  
 pyogenic, 168
- cholate stasis, 71
- cholestasis, 5, 153
- chromogranin, 183
- ciliated foregut cyst, 220, 224
- cirrhosis, 3, 5, 28–9, 75, 80, 95–6, 102, 123, 131  
 case study, 11  
 clinical features, 28  
 cytology, 29–31  
 diagnosis, 16  
 histology, 29, 110  
 nodular lesions, 74–81  
 radiology, 28, 101  
 with HCC, 100  
 with small HCC, 11
- CK7, 72, 77, 82, 84, 130, 132, 155, 174, 223, 259, 261–3, 265
- CK8, 116, 239
- CK18, 116
- CK19, 72, 77, 80, 82, 84, 125, 130, 132, 155, 223, 259, 261–3
- CK20, 155, 174, 259, 265
- clear cell sarcoma, 264
- clear cell tumors, 44, 48, 50, 156  
 metastatic, 197
- clear cells, 117
- clinical perspective, 3
- cloacogenic carcinoma, 264
- Clonorchis sinensis*, 20, 26, 139
- CNB, ix, 2–3, 214  
 evaluation, 33
- normal liver, 18
- percutaneous (transabdominal), 3
- sample acquisition, 274–6
- sample handling, 276–83
- secondary mass effect, 5  
*See also specific tumors*
- coagulative necrosis, 5
- colorectal adenocarcinoma, 40, 176
- combined hepatocellular–cholangiocarcinoma (CHCC–CC), 131
- computerized tomography *See* CT
- contrast-enhanced ultrasonography, 101
- copper pigments, 24
- copper-associated protein, 21, 24
- core needle biopsy *See* CNB
- crush artifacts, 5
- CT, 2, 13  
 angiomyolipoma, 58, 84  
 cirrhosis, 28  
 dysplastic nodules, 79  
 Epstein–Barr virus-associated smooth muscle tumor, 64  
 fatty liver disease, 25  
 granuloma, 89  
 HCA, 9  
 HCC, 101  
 hemangioma, 87  
 hepatocellular adenoma, 73  
 ICC, 140–1  
 large regenerative nodules, 95  
 spindle cell tumor, 207  
 squamous cell carcinoma, 289
- cystadenoma, 39, 67, 84, 212
- cystadenocarcinoma, 173, 183, 222, 224
- cystic degeneration, 218
- cystic intrahepatic cholangiocarcinoma, 224
- cystic mucinous adenocarcinoma, 55
- cystic tumors, 2, 50, 54, 214–33  
 case studies, 225–30  
 clinical features, 214  
 diagnostic algorithm, 216  
 metastatic, 178–80, 224  
 pathology, 215  
 radiology, 214–15  
 with epithelial lining, 215, 218–25  
 neoplastic, 221–5  
 nonneoplastic, 219–20  
 without epithelial lining, 215–18  
 neoplastic, 217–18  
 nonneoplastic, 215–17
- cysts, 2, 215  
 bile duct, 55, 219, 223  
 ciliated foregut, 220, 224  
 contents, 5  
 hemorrhagic, 217  
 hydatid, 216–17
- cytocentrifugation, 278–81
- cytokeratins, 205, 245, 259, 266
- cytology, 276  
 diagnostic algorithm, 61  
 histology vs., 273  
 liquid-based, 278–81  
 normal liver, 13–14  
*See also specific conditions*
- cytopathology report, 7–9
- Cytospin filters, 278
- D10, 84
- desmin, 86, 243
- developmental cystic disorders, 224, 228
- diagnosis, 7, 16, 62  
*See also specific tumors*
- diagnostic algorithms, 60–5  
 ancillary tests, 62  
 benign focal lesions, 67  
 clinical evaluation, 60–1  
 clinicopathologic correlation, 62  
 cystic lesions, 216  
 cytologic evaluation, 61  
 pediatric tumors, 235  
 radiologic evaluation, 61
- diastase digestion, 252
- differential diagnosis, 16  
*See also specific tumors*
- DiffQuik stain, 281
- dirty necrosis, 5, 152, 174
- dispersed cell pattern, 105
- DOG1, 266
- Dubin–Johnson pigment, 16, 21
- ductular cells, 142, 145
- dysplastic focus, 75
- dysplastic nodules, 76–80, 100, 263  
 ancillary tests, 79  
 clinical features, 77  
 cytology, 78  
 differential diagnosis, 79, 263  
 vs. HCC, 265  
 high-grade, 79  
 histology, 81  
 low-grade, 78, 81  
 radiology, 78–9
- EASL–EORTC, 60, 101
- EBER–ISH, 202
- Echinococcus granulosus*, 216–17
- EMA, 130, 155
- embryonal rhabdomyosarcoma, 236
- embryonal sarcoma *See* undifferentiated (embryonal) sarcoma
- endometrial carcinoma, 41, 177, 283
- endometrioid carcinoma, 174
- endoscopic retrograde cholangiopancreatography *See* ERCP
- endoscopic ultrasound (EUS), 275
- endoscopic ultrasound-guided FNA  
*See* EUS–FNA
- endothelial cells, 14–15
- Entamoeba histolytica*, 217
- Eosin Azure stain, 281
- Eosin Y stain, 281
- eosinophilic abscess, 217, 219, 225–9
- EpCAM, 130, 132
- epithelioid hemangioendothelioma (EHE), 39, 202, 212  
 ancillary tests, 202  
 cytology, 38, 202  
 differential diagnosis, 202, 266  
 histology, 202–3  
 radiology, 202
- Epstein–Barr virus-associated smooth muscle tumor, 64–5
- ERCP, 25, 157
- Escherichia coli*, 217

## INDEX

- estrogen receptor (ER), 166, 222, 253, 264
- European Association for the Study of Liver–European Organization for Research and Treatment of Cancer  
See EASL-EORTC
- EUS-FNA, 3
- gastrointestinal contaminants, 5
- Ewing sarcoma, 191, 236, 239
- extrahepatic constituents, 6
- in biopsy samples, 5
- extramedullary hematopoiesis, 201
- IF6, 84
- Factor VIII-associated antigen, 202
- familial adenomatous polyposis syndrome, 235
- Fast green stain, 281
- fat-containing cell tumors, 45, 50
- metastatic, 197
- fatty liver disease, 5, 17–20, 25
- clinical features, 17
- cytology, 19
- diagnosis, 19
- histology, 19
- radiology, 17, 25
- ferritin, 21, 24
- fibroinflammatory mass, 169
- fibrolamellar HCC, 125, 128–30
- ancillary tests, 130
- clinical features, 128
- cytology, 128
- differential diagnosis, 136, 263
- histology, 128
- radiology, 128
- fibroma, 88
- fibropolycystic disease, 20, 214
- fibrosarcoma, 198
- fine needle aspiration biopsy *See* FNAB
- fixation of samples, 273, 276–7
- FNAB, ix, 2–3, 214, 234, 265
- cell blocks, 283–6
- contraindications/complications, 273
- evaluation, 32
- percutaneous (transabdominal), 3
- sample acquisition, 274–6
- sample handling, 276–83
- See also specific tumors*
- focal fatty change, 66–8
- ancillary tests, 68
- clinical features, 66
- cytology, 66
- differential diagnosis, 68
- histology, 67
- radiology, 66
- focal nodular hyperplasia (FNH), 61, 66, 68–72
- ancillary tests, 72
- clinical features, 68
- cytology, 68
- differential diagnosis, 71
- histology, 71
- radiology, 68
- follicular dendritic cell tumor, 202
- formalin pigment, 21
- fungus abscesses, 217, 219
- gallbladder, adenocarcinoma, 176
- gastric adenocarcinoma, 176
- gastrointestinal contaminants, 7
- gastrointestinal stromal tumor *See* GIST
- germ cell tumors, 205–6
- giant cell tumors, 45, 50–1
- metastatic, 200–1
- giant cells, 118, 121
- multinucleated, 108
- GIST, 38–9, 174, 187, 198, 200, 265, 268
- case study, 267
- differential diagnosis, 266
- glandular tumors, 36, 39–46, 81–4
- metastatic, 174–5, 182
- glutamine synthetase, 68, 72, 77, 80, 117, 125, 132, 255–6, 262–3
- glycogen, 48, 67, 72, 73, 84, 109, 110, 117, 186, 197, 236, 237, 239, 251, 252, 266, 281
- glycogen storage disease, 252
- glypican-3, 80, 117, 125, 130, 132, 174, 205, 254–5, 262–3
- Gomori stain, 116, 123, 132, 250, 262
- Gomori's methenamine silver (GMS), 89, 91, 215, 217
- Gordon and Sweet stain, 250, 262
- GPC3 *See* glypican-3
- Gram stain, 215
- granular cell tumor, 88
- granuloma, 3, 39, 53, 88–9, 220
- ancillary tests, 89
- clinical features, 88
- cytology, 89
- histology, 89
- radiology, 88–9
- tuberculous, 5
- Grimelius stain, 183
- hamartoma
- bile duct *See* bile duct hamartoma
- mesenchymal *See* mesenchymal hamartoma
- HCA *See* hepatocellular adenoma
- HCC *See* hepatocellular carcinoma
- heat shock protein 70, 80, 117, 125, 256–7, 262–3
- hemangioma, cavernous 61, 66, 86–8
- clinical features, 86
- cytology, 86
- differential diagnosis, 87
- histology, 86
- radiology, 86
- hematologic malignancies, 201–2
- hematopoiesis, extramedullary, 15
- hematopoietic cell tumors, 46, 50, 52, 88–91
- hemochromatosis, 5, 27, 113, 253
- iron-free hepatocytes in, 109
- hemorrhagic cyst, 217
- hemosiderin, 21, 24, 27, 84
- hemosiderosis, 27
- hepatitis B, ix, 100
- hepatitis C, 100, 139
- hepatobiliary rhabdomyosarcoma, 191, 242–3
- ancillary tests, 243
- clinical features, 242
- cytology, 243
- differential diagnosis, 243
- histology, 243
- radiology, 243
- hepatoblastoma, 191, 234–40
- clinical features, 235
- cytology, 236–9
- differential diagnosis, 236, 240, 263
- fetal cell type, 264
- histology, 239–40
- radiology, 235–6
- teratoid features, 235, 239
- types of
- embryonal subtype, 237, 239
- fetal subtype, 236, 239
- macrotrabecular subtype, 237, 239
- mixed epithelial and mesenchymal type, 239
- small cell undifferentiated (SCUD) subtype, 239
- hepatocellular adenoma (HCA), 9, 16, 61, 66, 72–4
- ancillary tests, 73
- case study, 9–11
- clinical features, 72
- cytology, 72
- differential diagnosis, 73, 162
- histology, 72
- molecular characterization, 266
- radiology, 9, 72–3
- hepatocellular carcinoma (HCC), ix, 1–2, 16, 34–5, 96, 100–38, 230, 256
- ancillary tests, 115–17
- case studies, 132–6, 229–30
- clinical features, 100
- cytology, 102–10
- cell arrangement, 104–5
- cellular characteristics, 105–9
- differential diagnosis, 115, 263–4
- dysplasia, 263
- vs. dysplasia, 261–3, 265
- vs. metastatic tumors, 263
- fibrolamellar, 128–30
- histology, 110–15
- bare nuclei, 109
- cell arrangement, 103, 105, 110
- cellular characteristics, 110–13
- host background, 115
- host–tumor interface, 115
- tumor background, 113
- immunohistochemistry, 114
- lymphoepithelioma-like, 131
- mixed, 131–2
- moderately differentiated, 107
- molecular characterization, 267
- pathology, 101–2
- pediatric, 234
- poorly differentiated, 108
- prognostic and therapeutic targets, 267
- radiology, 61, 100–1, 131
- sarcomatoid, 131
- scirrhous, 130
- small *See* small HCC
- undifferentiated, 125, 130
- variants, 117–18
- clear cell change, 117, 264
- epithelioid pattern, 38, 263
- fatty change, 4, 111, 116–17, 134
- giant cell features, 110, 118, 121
- hepatocellular pattern, 37
- pleomorphic features, 117, 120
- small cell change, 115, 117, 119, 264
- spindle cell features, 118, 121

- well-differentiated, 106
- hepatocellular histogenesis, 261
- hepatocellular/epithelioid tumors, 36–9  
metastatic, 173–5  
*See also specific tumors*
- hepatocyte antigen *See* HepPar1
- hepatocyte nuclear factor 1 $\alpha$ -inactivated HCA, 266
- hepatocyte paraffin 1 *See* HepPar1
- hepatocytes, 13, 16  
large cell change, 74  
sibling variation, 13  
small cell change, 74–5
- hepatoid carcinoma, 205  
differential diagnosis, 263
- hepatolithiasis, 20
- HepPar1, 116, 130, 132, 174, 205, 254–5, 280
- HER2/neu, 177, 253, 264
- hilar cholangiocarcinoma, 139, 157–61  
clinical features, 157  
pathology, 158, 162  
radiology, 157
- histochemistry, 250–3, 262  
*See also specific tumors and stains*
- histology  
cytology vs., 273  
normal liver, 14–16  
sample handling, 283–6  
*See also specific conditions*
- histopathology report, 8
- HMB-45, 86, 266
- hyaline bodies, 128
- hyaline globules, 109, 112
- hydatid cyst, 216–17
- ICC *See* intrahepatic cholangiocarcinoma
- ICE *See* ROSE
- IgG4, 91
- immediate cytologic evaluation (ICE) *See* ROSE
- immunohistochemistry, 253–62  
HCC, 263–4  
poorly differentiated tumors, 266  
spindle cell tumor, 266
- incidentalomas, 66
- infantile hemangioma, 240–2, 276
- inflammatory cell tumors, 46, 50, 53, 88–91
- inflammatory HCA, 266
- inflammatory pseudotumor, 53, 89–91, 93, 220–1  
ancillary tests, 91  
case study, 91–4  
clinical features, 89  
cytology, 89  
differential diagnosis, 90, 264  
histology, 90  
radiology, 89
- intermediate cell carcinoma, 48, 185, 187, 192
- International Childhood Liver Tumor Study Group (SIOPEL), 235
- intrahepatic cholangiocarcinoma (ICC), ix, 1, 39, 139–69, 214  
ancillary tests, 155, 160  
case studies, 164–9  
clinical features, 139–40  
cytology, 144–7  
bare nuclei, 147  
cell arrangement, 143, 146  
cell characteristics, 146  
desmoplasia, 145, 149  
ductular proliferation type, 142  
intraductal-growth type, 141  
mass-forming type, 139, 140  
mucin secretion, 147  
periductal-infiltrating type, 141  
scant cell type, 142  
usual adenocarcinoma type, 142  
differential diagnosis, 154, 161–5  
vs. metastatic adenocarcinoma, 263
- histology, 152, 154  
cell arrangement, 148–50  
cellular characteristics, 149–51, 153–4  
host background, 152–3, 157  
host-tumor interface, 152  
phenotypic diversity, 149  
tumor background, 151–2, 154
- moderately differentiated, 149, 152, 154
- pathology, 143–4
- poorly differentiated, 39, 143, 144, 145, 150, 152
- radiology, 140–3
- variants, 156–7  
adenosquamous carcinoma, 156, 160  
clear cell carcinoma, 156, 264  
lymphoepithelioma-like carcinoma, 157  
mucinous carcinoma, 156  
mucoepidermoid carcinoma, 156  
sarcomatoid carcinoma, 157, 161  
signet ring cell carcinoma, 156, 161  
squamous cell carcinoma, 156, 160  
well differentiated, 149, 150, 151, 152
- intrahepatic constituents in biopsy samples, 5
- iron overload, 27–8
- iron stains, 253, 262 *See also* Perls stain
- iron-free focus, 76
- iron-free nodules, 76, 80
- Jab1, 267
- jaundice, obstructive, 27
- Kaposi sarcoma, 198
- Kasabach–Merritt syndrome, 86
- kidney, 7
- Klatskin needle, 274
- Klatskin tumor *See* hilar cholangiocarcinoma
- Klebsiella pneumoniae*, 217
- Kupffer cells, 4, 13–15
- large cell change, hepatocytes, 31, 67, 74
- large cell tumors, 44, 48, 50, 186
- large cells, 74
- large regenerative nodules, 74–81, 95–6, 124, 246  
ancillary tests, 77  
clinical features, 76  
cytology, 76  
differential diagnosis, 76  
histology, 76  
radiology, 76  
*See also specific nodule types*
- leiomyoma, 88
- leiomyosarcoma, 39, 174, 187, 198–9  
differential diagnosis, 266
- leukocyte common antigen, 266
- light green stain, 281
- lipofuscin, 16, 21–2, 72–3, 109
- lipoma, 88
- liposarcoma, 86, 136, 197, 200
- liquefactive necrosis, 5
- liquid-based cytology, 278–81
- liver  
abnormal, 16–32  
*See also specific conditions*  
anatomy, 1, 14  
blood supply, 1  
normal, 4, 13–16  
blood flow pattern, 13  
cytology, 13–14  
histology, 14–16, 18  
pigments, 16, 21  
radiology, 13
- liver cell dysplasia  
large cell change, 74  
small cell change, 74–5
- liver flukes, ix
- location of lesions, 3
- lung, adenocarcinoma, 177
- lymphangiectasia, 153
- lymphangioma, 88
- lymphoepithelioma-like carcinoma, 131, 157, 194
- lymphoma, 190–1, 193, 264
- macronodular tuberculosis, 90
- magnetic resonance cholangiopancreatography  
*See* MRCP
- magnetic resonance elastography *See* MRE
- magnetic resonance imaging *See* MRI
- malignant extrarenal rhabdoid tumor, 191
- malignant fibrous histiocytoma, 198
- Mallory–Denk bodies, 19, 68, 71, 79, 109, 112, 117, 128
- Masson trichrome stain, 251
- May–Grünwald–Giemsa (MGG) stain, 281
- megakaryocytes, 201
- Melan-A (Mart-1), 86
- melanin, 16, 21, 24
- melanoma  
differential diagnosis, 263–4  
metastatic, 185, 191, 194
- membrane filtration, 278–81
- Menghini needle, 274
- Merkel cell carcinoma, 264
- mesenchymal hamartoma, 218, 240  
ancillary tests, 240  
clinical features, 240  
cytology, 240–1  
differential diagnosis, 240  
histology, 240  
radiology, 240–1
- mesenchymal tumors, 84–8  
*See also specific types*
- mesothelial cells, 5, 6
- metastatic adenocarcinoma, 165
- metastatic hepatoid carcinoma, 174
- metastatic tumors, 171–3  
case studies, 205–9  
cell profile  
clear cell, 197  
cystic, 178–80  
fat-containing, 197  
giant cell, 200–1  
glandular, 174–5, 182

## INDEX

- metastatic tumors (cont.)  
 hepatocellular/epithelioid, 173–5  
 large cell, 194–5  
 mixed epithelioid–glandular, 178  
 mucinous, 174  
 oncocytic, 197  
 papillary, 174, 182  
 pleomorphic, 197, 199  
 polygonal, 195  
 small/intermediate cell, 181–94  
 spindle cell, 198–200  
 squamous cell, 180, 188  
 transitional, 197–8  
 clinical features, 171  
 diagnosis, 173  
 differential diagnosis, 178, 263  
 nonhepatocellular/non-glandular, 184  
 pathology, 171–3  
 radiology, 171–2  
 sites of origin, 173  
 methylene blue stain, 281  
 microabscesses, 3  
 Millipore filters, 278–9  
 mixed epithelioid–glandular tumors, 43, 46  
 metastatic, 178  
 mixed hepatobiliary carcinoma, 126–7  
 MMP-7, 139  
 MOC-31, 155, 259  
 molecular diagnosis, 265–7  
 morphology, 13–59  
 biopsies, 5  
 MRCP, 25, 140  
 MRE, 28  
 MRI, 2, 13  
 cirrhosis, 28  
 fatty liver disease, 25  
 fibroinflammatory mass, 169  
 focal nodular hyperplasia, 69  
 HCC, 101, 131  
 inflammatory pseudotumor, 91  
 large regenerative nodules, 76  
 nodular regenerative hyperplasia, 32  
 MUC1, 155  
 MUC2, 155  
 MUC3, 155  
 mucicarmine stain, 131, 155, 174  
 mucin, 5  
 mucinous carcinoma, 156  
 mucinous cystic neoplasm (MCN), 214, 221–3  
 ancillary tests, 222  
 clinical features, 221  
 cytology, 221–2, 225  
 differential diagnosis, 222  
 histology, 222  
 mucinous tumors, metastatic, 174  
 mucoepidermoid carcinoma, 156  
 mucosa-associated lymphoid tissue (MALT), 190  
*Mycobacterium tuberculosis* See macronodular tuberculosis; tuberculous granuloma  
 myelolipoma, 88  
 MyoD1, 243  
 myogenin, 243  
 naked nuclei See bare nuclei  
 nasopharynx, non-keratinizing undifferentiated carcinoma, 44, 48, 185, 187, 192, 218  
 NCAM See CD56  
 necrotic debris in biopsy samples, 5  
 necrotizing eosinophilic granuloma, 219  
 needle tract seeding, 100, 273  
 neoplastic aspirate, 38  
 nephroblastoma, differential diagnosis, 236  
 neuroblastoma  
 differential diagnosis, 236  
 metastatic, 245  
 neuroendocrine tumors, 39, 43, 174, 182, 184, 189  
 differential diagnosis, 191, 263–4  
 large cell, 194  
 polygonal cell subtype, 182  
 round cell subtype, 182  
 spindle cell subtype, 183  
 neurofibroma, 88  
 nodular hematopoiesis, 88  
 nodular regenerative hyperplasia, 5, 29–32  
 cytology, 29, 33  
 histology, 31  
 radiology, 29, 32  
 nodule-in-nodule lesions, 3, 96, 124  
 non-alcoholic steatohepatitis, 100  
 non-Hodgkin lymphoma, 185  
 non-small cell tumors, 194, 270  
 case study, 262–8  
 oncocytic cell tumors, 44, 48, 50  
 metastatic, 197  
*Opisthorchis viverrini*, 21, 139, 148  
 Orange G stain, 281  
 orcein stain, 72  
 ovarian mucinous carcinoma, 177  
 p53, 176  
 p63, 184, 187, 264  
 pale bodies, 109, 112, 128  
 pancreatic adenocarcinoma, 35, 176  
 cytology, 40  
 differential diagnosis, 165  
 pancreaticobiliary ductal carcinoma, 174  
 Papanicolaou stain, 19, 48, 117, 174, 187, 281–3  
 papillary tumors, 42–3  
 metastatic, 174, 182  
 paraganglioma, 52, 57, 195  
 parasitic cysts, 216–17  
 PAS stain, 89, 91, 131, 155, 174, 215, 217, 251  
 PAS-diastase stain, 89, 91, 131, 155, 215  
 pathology, 2–3  
 PAX-5, 184  
 pCEA, 116, 130, 132, 155, 174, 207, 214, 245, 257–8  
 PEComa See angiomyolipoma  
 pediatric tumors, 234–48  
 age at presentation, 234  
 case studies, 234–45  
 clinical features, 234  
 diagnostic algorithm, 235  
 hepatobiliary rhabdomyosarcoma, 242–3  
 hepatoblastoma, 234–40  
 infantile hemangioma, 240–2  
 mesenchymal hamartoma, 240  
 pathology, 234  
 undifferentiated (embryonal) sarcoma, 243–5  
 percutaneous transhepatic cholangiography  
 See PTC  
 periodic acid-Schiff See PAS stain; PAS-diastase stain  
 perisinusoidal space of Disse, 15  
 Perls stain, 80, 116, 253, 262  
 pheochromocytoma, 195  
 pigments, 16, 21–2, 108  
 pleomorphic cell tumors, 45, 50–1  
 metastatic, 197, 199  
 pleomorphic change, 117, 120  
 point-of-care testing, 287  
 polycystic liver disease, 214, 218  
 polygonal cell tumors, 44, 48  
 metastatic, 182, 195  
 poorly differentiated tumors, 265  
 differential diagnosis, 266  
 premalignant lesions, 75  
 preserved architecture, 14–16, 33  
 primary biliary cirrhosis, 20  
 primary sclerosing cholangitis, 20, 26, 139  
 primitive neuroectodermal tumor (PNET), 234, 236  
 progesterone receptor (PR), 177, 185, 264  
 prostatic acid phosphatase, 178  
 prostatic acinar adenocarcinoma, 43, 178  
 prostatic-specific antigen (PSA), 178  
 psammoma bodies, 43, 174  
 pseudoacinar cell pattern, 104–5, 110  
 pseudoacinar tumors, 43, 46  
 PTC, 25  
 pyogenic abscess, 53, 217–18  
 radiology, 2  
 diagnostic algorithm, 61  
 See also specific conditions  
 rapid on-site evaluation See ROSE  
 RCC See renal cell carcinoma  
 real-time telepathology systems, 288–9  
 Reed–Sternberg cells, 202  
 renal cell carcinoma, 115, 186, 194, 196  
 clear cell type, 264  
 metastatic, 36, 45  
 reticulin stains, 68, 72, 79, 250–1, 262  
 rhabdomyosarcoma  
 embryonal, 236  
 hepatobiliary See hepatobiliary rhabdomyosarcoma  
 rhodanine stain, 72  
 Romanowsky stains, 19, 26, 48, 105, 108, 117, 128, 174, 187, 197, 215, 217, 281  
 ROSE, 3, 89, 253, 286–7  
 advantages, 287  
 round cell tumors  
 metastatic, 182  
 S-100 protein, 86, 266  
 sample acquisition, 274–6  
 routes of, 274–5  
 sample handling, 276–83  
 crushing, 277  
 cytology vs. histology, 273  
 excess blood removal, 277  
 fixation, 273, 276–7  
 liquid-based cytology, 278–81  
 number of slides, 276  
 potential pitfalls, 278  
 staining, 273, 282–3



- sample preparation  
  leveling, 276  
  pushing (butterfly, facing), 276–7  
  sliding, 277
- sarcoma  
  clear cell, 264  
  Ewing, 191, 236, 239  
  Kaposi, 198  
  small cell, 264  
  synovial, 198  
  undifferentiated (embryonal)  
    See undifferentiated (embryonal)  
  sarcoma
- sarcomatoid carcinoma, 157
- sarcomatoid HCC, 131
- scant cell pattern, 142, 145
- schwannoma, 88  
  malignant, 198
- scirrhous HCC, 130
- secondary mass effect, 5
- serous cystadenoma, 39, 67, 84, 212
- siderotic nodules, 80
- signet ring cell carcinoma, 156, 161
- size of lesions, 3
- small cell carcinoma, 48, 183–91  
  neuroendocrine, 184
- small cell change, hepatocytes, 74–5
- small cell sarcoma, 264
- small cells, 74, 117
- small HCC, 119–25  
  ancillary tests, 125  
  clinical features, 119  
  cytology, 120–1  
  differential diagnosis, 123  
  early, 119  
  histology, 121–2  
  nodule-in-nodule, 122  
  progressed, 119  
  radiology, 119–20  
  with cirrhosis, 11
- small round blue cell tumors (SRBCT), 191, 234  
  differential diagnosis, 236
- small/intermediate cell tumors, 44, 48  
  metastatic, 181–94
- smooth muscle markers, 86
- solid compact cell pattern, 110
- solid lesions, 2
- solitary bile duct cyst, 55, 219, 223
- solitary fibrous tumor, 88
- spider cells, 84, 86, 197
- spindle cell tumors, 45, 50–1  
  characterization, 265  
  differential diagnosis, 266  
  metastatic, 183, 198–200, 206–7  
  See also *specific tumors*
- spindle cells, 118, 121
- squamous cell carcinoma, 160, 289
- squamous cell tumors, 44, 48, 156  
  metastatic, 180, 184, 188
- staining, 273, 282–3  
  See also *specific stains*
- steatohepatitis, 17, 135
- steatosis, 17, 19
- stellate cells, 15
- sulfur granules, 217
- suppurative necrosis, 5
- SurePath™, 278–9, 281
- synaptophysin, 183
- synovial sarcoma, 198
- techniques, 278–92  
  case studies, 289–92  
  CNB See CNB  
  FNAB See FNAB  
  ROSE See ROSE  
  sample acquisition, 274–6  
  sample handling, 276–86  
  staining, 273, 282–3  
  telepathology/telecytology, 287–9
- telepathology/telecytology, 287–9  
  real-time systems, 288–9  
  virtual slides, 287–8
- ThinPrep®, 278–80, 282
- Thorotrast, 139, 203, 291
- thrombomodulin, 64, 187
- thyroid transcription factor 1 See TTF-1
- tissue sampling See biopsy
- Toxocara catis/canis*, 217
- trabecular–sinusoidal cell pattern,  
  104–5, 110
- transitional cell tumors See urothelial  
  (transitional cell) tumors
- trichrome stain, 251
- TTF-1, 116, 132, 258–9
- tuberculous granuloma, 5, 217, 220
- tumors, 1, 32–52  
  cell profiles, 44, 48–50  
  patterns and profiles, 35–52  
  radiology, 2  
  See also *specific types*
- Ultrafast Pap stain, 281
- ultrasound  
  See contrast-enhanced ultrasonography
- undifferentiated carcinoma, 44, 125, 130, 176
- undifferentiated (embryonal) sarcoma, 191,  
  243–5  
  ancillary tests, 245  
  clinical features, 243  
  cytology, 243–4  
  differential diagnosis, 244  
  histology, 244  
  radiology, 243
- undifferentiated HCC, 130
- uroplakin III, 64, 187
- urothelial (transitional cell) tumors, 45, 48, 50,  
  187  
  metastatic, 197–8
- villin, 176
- vimentin, 86, 200, 202, 245
- virtual slides, 287–8
- von Meyenburg complexes See bile duct  
  hamartoma
- well-differentiated hepatocellular nodular  
  lesions, 246, 261
- Wilms' tumor, 239
- WT1, 177, 236
- xanthogranulomatous reaction, 46, 54, 89, 90, 94,  
  180, 217
- zellballen, 183
- Ziehl–Neelsen stain, 89, 91, 215